Neurocrine Biosciences (NBIX) Earning Somewhat Positive Media Coverage, Study Finds
News coverage about Neurocrine Biosciences (NASDAQ:NBIX) has trended somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.4827910366346 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- $75.70 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter (americanbankingnews.com)
- Neurocrine Biosciences : to Present New Long-Term Data Evaluating INGREZZA for the Treatment of Tardive Dyskinesia (4-traders.com)
- Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.03 Per Share (americanbankingnews.com)
- Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting (finance.yahoo.com)
- SITO Mobile, Ltd., (NASDAQ: SITO), Neurocrine Biosciences, Inc., (NASDAQ: NBIX), Puma Biotechnology, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
A number of research firms have recently weighed in on NBIX. Oppenheimer set a $85.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, November 14th. Robert W. Baird reiterated a “buy” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Barclays lifted their target price on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, November 2nd. Finally, Deutsche Bank reiterated a “buy” rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $78.88.
Neurocrine Biosciences (NASDAQ NBIX) traded up $1.71 during mid-day trading on Friday, reaching $73.60. 916,513 shares of the company were exchanged, compared to its average volume of 1,090,000. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the prior year, the business posted ($0.43) earnings per share. equities research analysts forecast that Neurocrine Biosciences will post -1.74 EPS for the current fiscal year.
In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the insider now directly owns 77,691 shares of the company’s stock, valued at approximately $5,794,194.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Darin Lippoldt sold 9,900 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The disclosure for this sale can be found here. Insiders have sold a total of 150,710 shares of company stock valued at $9,758,593 over the last three months. 4.80% of the stock is currently owned by insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.